Verifying…
Home / Drug A–Z / Vonozan Tablet 10 mg_

Vonozan Tablet 10 mg_

NAFDAC Reg. No. A4-101413 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Vonozan Tablet 10 mg_
NAFDAC number
A4-101413
Active ingredient
Vonoprazan Fumarate
Strength
13.36 mg
Form
Tablet
Pack size
4 x 7's (in Alu-PVDC blisters)
Manufacturer
Not listed
Applicant (holder)
Getz Pharma Nigeria Limited
Approved
30 Jul 2025
Status
Active View on NAFDAC ↗
Registration valid to
29 Jul 2030
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Vonozan Tablet 10 mg_ is on the NAFDAC register with an active registration (A4-101413). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Vonozan Tablet 10 mg_ is used for

From the official U.S. FDA label for vonoprazan fumarate, the active ingredient registered with NAFDAC.

What it is used for

VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. …

Possible side effects

The following serious adverse reactions are described elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] Bone Fracture [see Warnings and Precautions (5.4) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5) ] Vitamin B12 (Cobalamin) Deficiency [see Warnings and Precautions (5.6) ] Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.7) ] Fundic Gland Polyps [see Warnings and Precautions (5.9) ] Most common adverse reactions in VOQUEZNA-treated patients are: Healing of Erosive Esophagitis (≥2%): gastritis, diarrhea, abdominal d …

Do not use if

VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA. Reactions have included anaphylactic shock [see Adverse Reactions (6.2) and Description (11) ] . VOQUEZNA is contraindicated with rilpivirine-containing products [see Drug Interactions (7) ] . …

Warnings

Gastric Malignancy : Symptomatic response to treatment does not preclude the presence of gastric malignancy; consider additional follow-up and diagnostic testing. ( 5.1 ) Acute Tubulointerstitial Nephritis : Discontinue treatment and evaluate patients. ( 5.2 ) Clostridioides difficile -Associated Diarrhea (CDAD) : May be associated with an increased risk; use the shortest duration of treatment appropriate to the condition. ( 5.3 ) Bone Fracture, including Osteoporosis-related Fracture : Use the shortest duration of treatment appropriate to the condition. …

Pregnancy & breastfeeding

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VOQUEZNA during pregnancy. Healthcare providers are encouraged to register patients by calling 1-866-609-1612 or visiting https://voqueznapregnancyregistry.com/ . Risk Summary There are no adequate and well-controlled studies of vonoprazan in pregnant women. …

Storage

Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Vonozan Tablet 10 mg_

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Vonozan Tablet 10 mg_

What is in Vonozan Tablet 10 mg_?

Vonozan Tablet 10 mg_ contains Vonoprazan Fumarate (13.36 mg), as tablet, according to its NAFDAC registration record.

Is Vonozan Tablet 10 mg_ registered with NAFDAC?

Yes. Vonozan Tablet 10 mg_ is listed on the NAFDAC register under registration number A4-101413, and its registration is active as of 5 November 2026.

Has Vonozan Tablet 10 mg_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Vonozan Tablet 10 mg_ in our automatically synced alert list.

How can I check that my pack of Vonozan Tablet 10 mg_ is genuine?

Run a free authenticity scan with the NAFDAC number A4-101413, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Vonozan Tablet 10 mg_ used for?

VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicilli (Summarised from the official U.S. FDA label for vonoprazan fumarate. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Vonozan Tablet 10 mg_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.